Abstract
Systemic antibiotics are the group of drugs most commonly used in children. Off-label antibiotic use in children is still common in the community and in hospitals, mostly because of young age, dosage, or frequency of drug application. There is an important incentive gap that hinders paediatric drug development resulting from a series of factors, such as small market size, a predominance of off-patent use, no incentives for generic drug manufacturers, and a greater complexity of drug development. The latter is due to varying capacities of drug absorption and metabolism during growth and maturation and the need for oral formulations in neonates and infants. High ethical barriers, combined with concerns of parents about drug safety, further complicate the conduct of clinical studies in children. While many off-patent antibiotics today are labelled for use in children, newer substances such as fluoroquinolones, azithromycin, linezolid, or daptomycin are not. This is of concern in the light of emerging multidrug-resistant pathogens.
Keywords: Antibiotic therapy, children, infants, neonates, off-label use, off-licensed, unlicensed, frequency of drug application, paediatric, adverse drug reaction
Current Drug Targets
Title:Antibiotic Use in Children - Off-Label Use
Volume: 13 Issue: 7
Author(s): Walter Zingg and Klara M. Posfay-Barbe
Affiliation:
Keywords: Antibiotic therapy, children, infants, neonates, off-label use, off-licensed, unlicensed, frequency of drug application, paediatric, adverse drug reaction
Abstract: Systemic antibiotics are the group of drugs most commonly used in children. Off-label antibiotic use in children is still common in the community and in hospitals, mostly because of young age, dosage, or frequency of drug application. There is an important incentive gap that hinders paediatric drug development resulting from a series of factors, such as small market size, a predominance of off-patent use, no incentives for generic drug manufacturers, and a greater complexity of drug development. The latter is due to varying capacities of drug absorption and metabolism during growth and maturation and the need for oral formulations in neonates and infants. High ethical barriers, combined with concerns of parents about drug safety, further complicate the conduct of clinical studies in children. While many off-patent antibiotics today are labelled for use in children, newer substances such as fluoroquinolones, azithromycin, linezolid, or daptomycin are not. This is of concern in the light of emerging multidrug-resistant pathogens.
Export Options
About this article
Cite this article as:
Zingg Walter and M. Posfay-Barbe Klara, Antibiotic Use in Children - Off-Label Use, Current Drug Targets 2012; 13 (7) . https://dx.doi.org/10.2174/138945012800675777
DOI https://dx.doi.org/10.2174/138945012800675777 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery Proteomic and Bioinformatics Tools to Understand Virulence Mechanisms in Staphylococcus aureus
Current Proteomics Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Adenotonsillar Disease
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections
Current Topics in Medicinal Chemistry Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients
Current Pharmaceutical Biotechnology Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians
Recent Patents on Anti-Infective Drug Discovery Antimicrobial Peptides as Anti-biofilm Agents in Medical Implants
Current Topics in Medicinal Chemistry Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Intracellular Life of Coxiella burnetii in Macrophages: Insight into Q Fever Immunopathology
Current Immunology Reviews (Discontinued) The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Current Neurovascular Research Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets